ivosidenib — United Healthcare

Initial criteria

• Diagnosis of oligodendroglioma
• Disease is recurrent or progressive
• Presence of BOTH of the following: IDH1 mutation AND 1p19q codeletion
• Disease is WHO grade 2 or 3

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Tibsovo therapy

Approval duration

12 months